Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
8,716 total articles
Credo (CRDO) is a high-growth AI-infrastructure play whose recent pullback has handed active traders a clear entry with defined risk. The company reported roughly $407M in the most recent quarter (about +201% YoY) and industry-leading gross margins near 68.5%. At a market cap around $17.7B and P/E north of 50, downside is real — but a mid-term trad…
Woodside trades near its 52-week high with a market cap of $45.3B and a 4.5% yield. Positive macro headlines around LNG have driven interest, but evidence of capped upside, bearish momentum and elevated short activity argue for a tactical short. Entry $23.70, target $20.00, stop $25.50 - mid-term swing (45 trading days).
XLG offers concentrated exposure to the market’s largest, fastest-growing names. Recent earnings momentum among mega-cap technology leaders supports a tactical long exposure, but concentration and macro sensitivity mean risk must be capped. Trade plan: enter $80.00, stop $72.00, target $95.00 for a mid-term trade (45 trading days).
THLLY (Thales unsponsored ADR) is trading above its short- and medium-term moving averages with bullish momentum indicators and recent volume that suggests renewed investor interest. With Europe increasing defense budgets, growing demand for public-safety and post-quantum cryptography solutions, and Thales’ exposure across defense, aerospace, and c…
Urban Outfitters is trading at an attractive multiple relative to its growth profile thanks to a fast-growing Nuuly subscription business and a clean balance sheet. With free cash flow of $402.7M and virtually no debt, the company has room to invest in customer acquisition, margin expansion and buybacks. This trade idea lays out an actionable mid-t…
Aimco (AIV) is in the final stages of a plan of sale and liquidation. The company has declared initial distributions and signed large asset-sale agreements, but high leverage, negative free cash flow, and a narrow window for Q2 payouts create an asymmetric near-term setup for downside. This trade targets a short-term move over the next 10 trading d…
Quanta Services (PWR) sits at the intersection of power, renewables, and communications infrastructure. With a market cap north of $83 billion, a $44 billion backlog, and free cash flow of roughly $1.52 billion, the company can be an effective way to play the multiyear electrification and data-center build cycle. We present a long trade with clear …
Newmont (NEM) is trading below near-term resistance after a volatile gold patch tied to geopolitical headlines. The company’s balance sheet, record free cash flow, and attractive valuation metrics argue for a tactical long. I recommend entering at the current level with a mid-term horizon and disciplined stop.
Micron is the dominant beneficiary of the AI-driven memory cycle. Recent pullbacks over speculative threats like Google’s TurboQuant and capex worries are noise relative to the supply-demand gap for high-bandwidth memory. I am adding to my position with a clear entry, stop and target: this is a mid-term trade sized for active risk management.
RH (Restoration Hardware) plunged after a weak Q4 print and tariff-related headwinds. The sell-off pushes the stock to an attractive entry: P/E in the mid-20s, P/S under 1x, positive free cash flow, and a deeply oversold technical profile. High leverage is the headline risk, but a defined trade with a $100 stop and a $180 target offers attractive r…
An activist investor pushing a 'Year of Efficiency' gives Snap a credible path to higher margins and cash flow. At a $8.3B market cap with positive free cash flow and reasonable price-to-sales, the setup looks actionable. We lay out an entry, stop, targets and a balanced risk framework tied to litigation and ad-market cyclicality.
United Therapeutics' second positive TETON outcome for nebulized Tyvaso plus encouraging ralinepag data clears a runway of regulatory catalysts and upside. The balance sheet and recurring revenue base justify a continued 'Strong Buy' stance. This trade idea lays out an actionable entry at the current level, a protective stop, and a target tied to r…
Joby is trading near $8.28 with a market cap around $8.1B, a strong cash position ($4.01B) and a recent Type Inspection Authorization flight. With FAA progress and manufacturing scale plans, the risk/reward looks attractive for a disciplined long trade targeting $14.00, while limiting downside with a $6.00 stop.
Sportradar’s recent deal flow, margin expansion and select institutional buying argue the company is moving from growth-only to quality growth. At $16.64 the stock is trading well below its 52-week high but still at a premium multiple; this trade idea targets a re-rating catalyzed by product integrations and rights wins while respecting execution a…
Cadre Holdings dropped sharply from recent highs amid a broad defense-stock meltdown. Fundamentals - including $56.8M in free cash flow, a healthy current ratio and manageable leverage - argue the pullback is an opportunity. I upgrade CDRE to Strong Buy for a mid-term swing: enter $31.72, stop $28.00, target $42.00 (45 trading days).
Freshworks is trading near the low end of its 52-week range after a year of volatility. The stock now carries a sub-$2.3B market cap, positive free cash flow ($236.7M), and a P/E in the low-teens — metrics that look attractive relative to the company's 16% reported revenue growth and cleaner profitability. We upgrade to a Tactical Buy and lay out a…
Lamb Weston (LW) has been punished after an ERP-related sales disruption and softer pricing, but underlying cash flow, reasonable valuation and improving technicals suggest fiscal Q3 weakness could be the low-risk entry for a mid-term rebound. This is a swing trade idea with entry, stop and target defined and a clear risk framework.
Microsoft's pullback has created a high-quality, lower-risk entry for disciplined buyers. With a fortress balance sheet, $77.4B of free cash flow and a trailing EPS of $16.06, I upgrade MSFT to a Buy on a plan to accumulate at 22x earnings ($353.32). The trade targets a recovery back toward the $440 area over the next 180 trading days while protect…
Argan reported a clean Q4 earnings beat driven by margin expansion and an outsized backlog tied to data-center and power projects. The stock has power behind it - a near-zero debt profile, strong free cash flow, and technical momentum - but it trades at a premium. This trade idea lays out a mid-term (45 trading days) entry, stop and target, plus th…
Micron sold off after headlines about Google's TurboQuant and a volatile market swing, but core demand for high-bandwidth memory (HBM) and a rising capital plan keep the story intact. Fundamentals - strong cash flow, expanding capex to capture AI demand, and earnings power - combined with a 3:1+ reward-to-risk on this setup argue for a tactical lon…
We upgrade Abbott Laboratories (ABT) to Buy ahead of Q1 results. At $103.52, the shares trade below near-term averages with a PE ~27.6, a healthy dividend yield (~2.3%), and strong free cash flow ($7.4B). Recent weakness centers on diagnostics and nutrition, but medical devices growth, a manageable balance sheet (debt/equity 0.25), and the $21B Exa…
Lumentum is squarely in the middle of an optical upgrade cycle for AI data centers. With an S&P 500 addition, a $2 billion strategic allocation from NVIDIA, and accelerating revenue and earnings prints, LITE has momentum. Valuation is rich, so the trade is a tactical long with a defined stop and multi-horizon targets.
Unity Bancorp (UNTY) delivered record 2025 earnings, double-digit loan and deposit growth and a tidy return on equity, yet it trades at about 9x earnings and 1.5x book. That combination of earnings momentum, attractive multiples and benign technicals supports a tactical long. This trade sets an entry near current levels, a disciplined stop, and a t…
CRISPR Therapeutics (CRSP) looks to be at a commercial turning point as Casgevy patient initiations and early sales accelerate. With a $2.33B cash cushion, multiple pipeline readouts ahead and heavy short interest amplifying volatility, this trade idea targets asymmetric upside while protecting capital with a strict stop. Entry $49.75, target $68.0…
Costamare looks protected in the immediate window thanks to contract coverage, a steady dividend and balance-sheet metrics that keep downside limited. At the same time, six newbuilds, cyclical freight-rate risk and a stretched market multiple relative to shipping volatility argue for caution over the next 1-3 months. The trade: buy the bounce now f…
